OXiGENE is a biopharmaceutical company whose mission is finding and developing new and improved therapeutics that can deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions.

Thursday, June 25, 2009
OXiGENE Initiates Phase 2 Trial of ZYBRESTAT for Ophthalmology

Wednesday, June 17, 2009
OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer